January 12, 2023

Dermavant to Present Data from Multiple Studies of ...

Read More

November 22, 2022

Dermavant Launches First Commercial for VTAMA ...

Read More

November 8, 2022

Dermavant Announces Highly Favorable Results from ...

Read More

October 13, 2022

Dermavant to Present Data from Multiple Clinical T ...

Read More

September 7, 2022

Fortune and Great Place to Work® Name ...

Read More

August 24, 2022

Dermavant to Present New Data from Phase 3 Trial P ...

Read More

June 28, 2022

VTAMA® (tapinarof) cream, 1% PSOARING ...

Read More

May 24, 2022

FDA Approves Dermavant’s VTAMA® (tap ...

Read More

March 25, 2022

Dermavant Showcases New Long-Term Durability and T ...

Read More

March 11, 2022

Dermavant to Present New Data from the Phase 3 PSO ...

Read More

March 8, 2022

Dermavant Appoints Nancy Beesley to its Board of D ...

Read More

January 15, 2022

Dermavant Presents New Patient Satisfaction Data f ...

Read More

January 7, 2022

Dermavant to Present New Data from Phase 3 PSOARIN ...

Read More

December 9, 2021

Dermavant Announces Publication of PSOARING 1  ...

Read More

December 9, 2021

The New England Journal of Medicine: Phase 3 Trial ...

Read More

September 30, 2021

Dermavant Showcases New Long-Term Data from Phase ...

Read More

September 23, 2021

Dermavant to Present New Data on Phase 3 PSOARING ...

Read More

September 9, 2021

Dermavant Announces First Patient Dosed in ADORING ...

Read More

August 10, 2021

Dermavant Announces FDA Acceptance for Filing of N ...

Read More

June 7, 2021

Dermavant Announces $200 Million of Financing ...

Read More